Author: Jane Edwards|| Date Published: January 9, 2023
An industry team consisting of Battelle, Andelyn Biosciences and AmplifyBio has secured a position on an eight-year, $149 million contract vehicle to provide support services for a National Institutes of Health research program focused on the development of treatments for neurological conditions.
The Central Ohio-based team will provide nonclinical and manufacturing support to help the National Institute of Neurological Disorders and Stroke advance the translational development of biological treatments under the multiple-award, indefinite-delivery/indefinite-quantity contract, Battelle said Friday.
“The contract will be used to advance innovative therapies, including cell and gene therapy, for a broad variety of neurological diseases,” said Drew Cawthon, business line director for Battelle’s life science research.
Jerry Hacker, executive vice president and chief commercial officer at AmplifyBio, said the company looks forward to contributing its preclinical study and therapy analytics capabilities to pursue the development of treatments for neurological conditions.
Battelle brings to the partnership its decades of experience in federal government contracting and assay and integration services to support regulatory approvals.
CesiumAstro, a global provider of space and defense communications systems and satellites, has acquired artificial intelligence company Vidrovr to strengthen its…
BigBear.ai, provider of artificial intelligence decision intelligence, has closed fiscal 2025 with what CEO Kevin McAleenan, a three-time Wash100 winner,…
L3Harris Technologies has appointed Kenneth “Ken” Sharp as senior vice president and chief financial officer, succeeding current CFO Ken Bedingfield, effective…
Boeing has secured a $166.8 million cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract to support software sustainment and modernization efforts for the U.S. Navy’s…
